BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16820007)

  • 1. Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.
    Sadri-Vakili G; Menon AS; Farrell LA; Keller-McGandy CE; Cantuti-Castelvetri I; Standaert DG; Augood SJ; Yohrling GJ; Cha JH
    Eur J Neurosci; 2006 Jun; 23(12):3171-5. PubMed ID: 16820007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease.
    Benn CL; Luthi-Carter R; Kuhn A; Sadri-Vakili G; Blankson KL; Dalai SC; Goldstein DR; Spires TL; Pritchard J; Olson JM; van Dellen A; Hannan AJ; Cha JH
    J Neuropathol Exp Neurol; 2010 Aug; 69(8):817-27. PubMed ID: 20613636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice.
    Meade CA; Deng YP; Fusco FR; Del Mar N; Hersch S; Goldowitz D; Reiner A
    J Comp Neurol; 2002 Jul; 449(3):241-69. PubMed ID: 12115678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice.
    Reiner A; Del Mar N; Deng YP; Meade CA; Sun Z; Goldowitz D
    J Comp Neurol; 2007 Dec; 505(6):603-29. PubMed ID: 17948889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
    Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
    Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.
    Wang YL; Liu W; Wada E; Murata M; Wada K; Kanazawa I
    Neurosci Res; 2005 Nov; 53(3):241-9. PubMed ID: 16095740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis.
    Ryan AB; Zeitlin SO; Scrable H
    Neurobiol Dis; 2006 Nov; 24(2):419-27. PubMed ID: 16978870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice.
    Young D; Mayer F; Vidotto N; Schweizer T; Berth R; Abramowski D; Shimshek DR; van der Putten PH; Schmid P
    PLoS One; 2013; 8(9):e75108. PubMed ID: 24086450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
    Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
    Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease.
    Spektor BS; Miller DW; Hollingsworth ZR; Kaneko YA; Solano SM; Johnson JM; Penney JB; Young AB; Luthi-Carter R
    Brain Res Mol Brain Res; 2002 Jun; 102(1-2):118-28. PubMed ID: 12191502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.
    Smith R; Petersén A; Bates GP; Brundin P; Li JY
    Neurobiol Dis; 2005 Dec; 20(3):673-84. PubMed ID: 15967669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Wanderer J; Morton AJ
    Histochem Cell Biol; 2007 May; 127(5):473-84. PubMed ID: 17285342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death.
    Roze E; Betuing S; Deyts C; Marcon E; Brami-Cherrier K; Pagès C; Humbert S; Mérienne K; Caboche J
    FASEB J; 2008 Apr; 22(4):1083-93. PubMed ID: 18029446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation.
    Morton AJ; Lagan MA; Skepper JN; Dunnett SB
    J Neurocytol; 2000 Sep; 29(9):679-702. PubMed ID: 11353291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
    Dunah AW; Jeong H; Griffin A; Kim YM; Standaert DG; Hersch SM; Mouradian MM; Young AB; Tanese N; Krainc D
    Science; 2002 Jun; 296(5576):2238-43. PubMed ID: 11988536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.
    Björkqvist M; Petersén A; Bacos K; Isaacs J; Norlén P; Gil J; Popovic N; Sundler F; Bates GP; Tabrizi SJ; Brundin P; Mulder H
    Hum Mol Genet; 2006 May; 15(10):1713-21. PubMed ID: 16613897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.